Phase 2Completed

Study Assessing Immunogenicity and Safety of IC43 In Intensive Care Patients

A Phase 2 Pilot Study Assessing Immunogenicity and Safety of IC43 in Intensive Care Patients

Sponsor
Valneva Austria GmbH (Industry)
Enrollment
400 enrolled
Conditions
Pneumonia, Ventilator-Associated
Interventions
IC43; Placebo
Ages
adults, older adults
Registry
NCT00876252

Full record on ClinicalTrials.gov

From the registry

Randomized, placebo-controlled, partially blinded phase 2 pilot study. Multicenter study (approximately 50 centers) in approximately 9 countries. Proposed start date is December 2008. The study duration per patient is estimated to be 90 days. Overall study duration is estimated to be 12-18 months.

Primary outcomes

  • Immunogenicity at day 14 as determined by OprF/I specific IgG antibody titer measured by ELISA in patients receiving IC43 or placebo

History

  1. Last registry update

  2. Primary completion

  3. Registered

  4. Started